Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously

This article was originally published in The Gray Sheet

Executive Summary

Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.

Advertisement

Related Content

Imaging Groups Oppose CMS Coverage Proposal For Beta-Amyloid PET
Trial-Only Medicare Coverage Proposed For PET Alzheimer’s Scans
Medicare Panel Finds Little Support For Amyloid PET Imaging Changes
Merck Partners On Alzheimer’s Diagnostic With GE Healthcare
CMS Issues List Of Potential National Coverage Determination Topics
Reimbursement In Brief
News In Brief
Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT031721

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel